# Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)

> **NCT00941863** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 158 (actual)

## Conditions studied

- Carcinoma

## Interventions

- **DRUG:** Sorafenib 100 mg (50-mg tablet)
- **DRUG:** Sorafenib 200 mg (50-mg tablet)
- **DRUG:** Sorafenib 400 mg (50-mg tablet)
- **DRUG:** Sorafenib 400 mg (200-mg tablet)
- **DRUG:** Sorafenib 400 mg (Expansion)

## Key facts

- **NCT ID:** NCT00941863
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** 2005-05
- **Final completion:** 2008-04
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2016-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00941863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00941863, "Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00941863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*